

Rescue angioplasty versus conservative treatment or repeat thrombolysis (the REACT trial)

Submission date 16/11/2001	Recruitment status Stopped	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 16/11/2001	Overall study status Stopped	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 15/07/2009	Condition category Circulatory System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr AH Gershlick

Contact details
Academic Dept of Cardiology
Clinical Sciences Wing
Glenfield General Hospital
Leicester
United Kingdom
LE3 9QP
+44 (0)116 256 3038
agershlick@aol.com

Additional identifiers

Protocol serial number
RG/98005

Study information

Scientific Title

Acronym

REACT

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Myocardial infarction

Interventions

Patients to be randomised to:

1. Rescue Percutaneous Transluminal Coronary Angioplasty (PTCA) - stent placement or platelet glycoprotein receptor blockers and the use of intra-aortic balloon pulsation will be guided by clinical need
2. Rescue thrombolysis with tissue Plasminogen Activator (tPA), reteplase, tenecteplase
3. Conservative treatment - intravenous (iv) heparin for 24 hours

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s)

Not provided at time of registration

Completion date

01/03/2004

Reason abandoned (if study stopped)

Other ongoing clinical trials, as well as the introduction of the new thrombolytic agent tenecteplase (and the concomitant unlicensed use of low-molecular-weight heparin), limited the number of suitable candidates for participation. Because of declining trial recruitment and a finite funding period, the steering committee terminated enrolment in the trial in March 2004.

Eligibility

Key inclusion criteria

1. Patients with acute myocardial infarction presenting within 6 hours who have received aspirin and an accepted thrombolytic drug
2. Aged 21 - 85 years and able to give informed consent
3. Ability to undertake coronary intervention within 12 hours of onset of chest pain
4. All patients to have failed reperfusion 90 minutes from the start of thrombolysis

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/12/1999

Date of final enrolment

01/03/2004

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Academic Dept of Cardiology

Leicester

United Kingdom

LE3 9QP

Sponsor information

Organisation

British Heart Foundation (UK)

ROR

<https://ror.org/02wdwnk04>

Funder(s)

Funder type

Charity

Funder Name

British Heart Foundation (UK) (ref: RG/98005)

Alternative Name(s)

The British Heart Foundation, the_bhf, BHF

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	29/12/2005		Yes	No
Results article	results	07/07/2009		Yes	No